Tags

Type your tag names separated by a space and hit enter

Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism.
Eur J Endocrinol. 2002 Oct; 147(4):467-71.EJ

Abstract

OBJECTIVE

To compare the clinical efficacy and safety of high-dose (5 mg/day) and low-dose (2.5 mg/day) finasteride in the treatment of hirsutism in women.

DESIGN

A prospective, randomized and controlled clinical trial.

METHODS

Fifty-six hirsute women with moderate to severe hirsutism were prospectively evaluated to see the effects of low-dose (2.5 mg/day) and high-dose (5 mg/day) finasteride. Patients were randomly divided into two treatment groups. Group I (n=29) received 2.5 mg finasteride/day and group II (n=27) received 5 mg finasteride/day orally for 1 year. Hirsutism score, body mass index and hormonal parameters (FSH, LH, estradiol, androstenedione, testosterone, free testosterone, 17alpha-hydroxyprogesterone, dehydroepiandrosterone sulfate and sex hormone-binding globulin) were measured in all the patients before treatment and repeated at six-monthly intervals.

RESULTS

The hirsutism scores decreased significantly at months 6 and 12 from a mean+/-s.d. of 18.4+/-4.6 to 13.3+/-5.2 (P<0.001) and 18.4+/-4.6 to 8.6+/-4.2 (P<0.001) in group I and from 18.7+/-5.2 to 13.9+/-5.3 (P<0.001) and 18.7+/-5.2 to 10.3+/-5.0 (P<0.001) in group II respectively. No significant changes in the blood chemistry and hormonal parameters except estradiol levels were observed. No serious side-effects were seen in the two groups. In group II, estradiol levels increased significantly at 6 and 12 months.

CONCLUSIONS

In this study, hirsutism scores decreased significantly at 6 and 12 months in both groups I and II. Low-dose (2.5 mg/day) finasteride is safe and cost effective in the treatment of hirsutism and may be used instead of high-dose finasteride (5 mg/day) therapy.

Authors+Show Affiliations

Bayram F
Department of Endocrinology and Metabolism, Faculty of Medicine, Erciyes University, Kayseri, Turkey. fbayram@erciyes.edu.tr
Müderris II
No affiliation info available
Güven M
No affiliation info available
Keleştimur F
No affiliation info available

MeSH

17-alpha-HydroxyprogesteroneAdolescentAdultAndrostenedioneDehydroepiandrosterone SulfateEnzyme InhibitorsEstradiolFemaleFinasterideFollicle Stimulating HormoneHirsutismHumansLuteinizing HormoneSex Hormone-Binding GlobulinTestosterone

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12370107

Citation

Bayram, Fahri, et al. "Comparison of High-dose Finasteride (5 Mg/day) Versus Low-dose Finasteride (2.5 Mg/day) in the Treatment of Hirsutism." European Journal of Endocrinology, vol. 147, no. 4, 2002, pp. 467-71.
Bayram F, Müderris II, Güven M, et al. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol. 2002;147(4):467-71.
Bayram, F., Müderris, I. I., Güven, M., & Keleştimur, F. (2002). Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. European Journal of Endocrinology, 147(4), 467-71.
Bayram F, et al. Comparison of High-dose Finasteride (5 Mg/day) Versus Low-dose Finasteride (2.5 Mg/day) in the Treatment of Hirsutism. Eur J Endocrinol. 2002;147(4):467-71. PubMed PMID: 12370107.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. AU - Bayram,Fahri, AU - Müderris,I Ipek, AU - Güven,Muhammed, AU - Keleştimur,Fahrettin, PY - 2002/10/9/pubmed PY - 2002/12/10/medline PY - 2002/10/9/entrez SP - 467 EP - 71 JF - European journal of endocrinology JO - Eur J Endocrinol VL - 147 IS - 4 N2 - OBJECTIVE: To compare the clinical efficacy and safety of high-dose (5 mg/day) and low-dose (2.5 mg/day) finasteride in the treatment of hirsutism in women. DESIGN: A prospective, randomized and controlled clinical trial. METHODS: Fifty-six hirsute women with moderate to severe hirsutism were prospectively evaluated to see the effects of low-dose (2.5 mg/day) and high-dose (5 mg/day) finasteride. Patients were randomly divided into two treatment groups. Group I (n=29) received 2.5 mg finasteride/day and group II (n=27) received 5 mg finasteride/day orally for 1 year. Hirsutism score, body mass index and hormonal parameters (FSH, LH, estradiol, androstenedione, testosterone, free testosterone, 17alpha-hydroxyprogesterone, dehydroepiandrosterone sulfate and sex hormone-binding globulin) were measured in all the patients before treatment and repeated at six-monthly intervals. RESULTS: The hirsutism scores decreased significantly at months 6 and 12 from a mean+/-s.d. of 18.4+/-4.6 to 13.3+/-5.2 (P<0.001) and 18.4+/-4.6 to 8.6+/-4.2 (P<0.001) in group I and from 18.7+/-5.2 to 13.9+/-5.3 (P<0.001) and 18.7+/-5.2 to 10.3+/-5.0 (P<0.001) in group II respectively. No significant changes in the blood chemistry and hormonal parameters except estradiol levels were observed. No serious side-effects were seen in the two groups. In group II, estradiol levels increased significantly at 6 and 12 months. CONCLUSIONS: In this study, hirsutism scores decreased significantly at 6 and 12 months in both groups I and II. Low-dose (2.5 mg/day) finasteride is safe and cost effective in the treatment of hirsutism and may be used instead of high-dose finasteride (5 mg/day) therapy. SN - 0804-4643 UR - https://www.unboundmedicine.com/medline/citation/12370107/Comparison_of_high_dose_finasteride__5_mg/day__versus_low_dose_finasteride__2_5_mg/day__in_the_treatment_of_hirsutism_ DB - PRIME DP - Unbound Medicine ER -